Download as a PDF
Previous PAD Refills newsletters
Conclusion: The American College of Physicians 2024 guideline advises against adding a DPP4 inhibitor (DPP4i) to metformin because they do not improve patient-important outcomes (morbidity, mortality). DPP4i are relatively costly and people are more likely to benefit from SGLT2 inhibitors (SGLT2i) or GLP1 agonists (GLP1a).
The BC Provincial Academic Detailing (PAD) service continues to deliver the topic T2DM Focused Update: SGLT2 Inhibitors & GLP1 Agonists. This topic highlights the evidence of SGLT2i and GLP1a in improving morbidity and mortality in people with type 2 diabetes.
Death from any cause | RR 1.01 (95%CI 0.94 to 1.08) | no difference; high certainty of evidence |
Major adverse cardiovascular events | RR 1.00 (95%CI 0.94 to 1.06) | |
Hospitalization for heart failure | RR 1.06 (95%CI 0.96 to 1.17) | |
Chronic kidney disease | RR 1.07 (95%CI 0.95 to 1.21) |
1QASEEM Ann Intern Med 2024 Apr 29 (PMID:38639546); 2DRAKE Ann Intern Med 2024 Apr 19 (PMID:38639549); 3Cochrane Database Syst Rev 2021;10:CD013650 (PMID: 34693515); 4SHI BMJ 2023;381:e074068 (PMID:37024129); 5McKesson Pharmaclik; 6Health Canada Drug Product Database Trajenta®; 7ISKANDER CMAJ 2020;192:E351-60 (PMID:32392523); 8BC PAD Service PAD Refill Dec 2022; 9TSAPAS Ann Intern Med 2020;173:278-86 (PMID:32598218); 10YKI-JARVINEN Diabetes Care 2013;12:3875-81 (PMID:24062327); 11CARMELINA JAMA 2019;321:69-79 (PMID:30418475)
Enter your email address to subscribe to updates of this page.